source
- Xenon shares tumble up to 30% after pausing depression trial over neuropsychiatric eventsXenon Pharmaceuticals announced it is pausing enrollment in its depression trial for the drug azetukalner after neuropsychiatric adverse events emerged that were not observed in earlier testing. A…
- Roche opens new research center in Boston, expanding its local presenceRoche announced the opening of a new research facility in Boston, adding to its existing operations in the city. The center will focus on early-stage drug discovery and will house several hundred…